Status:
COMPLETED
Zoledronate in Preventing Osteoporosis in Patients With Primary Malignant Glioma
Lead Sponsor:
Duke University
Collaborating Sponsors:
Novartis
National Institute of Neurological Disorders and Stroke (NINDS)
Conditions:
Brain Tumors
Osteoporosis
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
RATIONALE: Zoledronate may prevent bone loss in patients with primary malignant glioma. PURPOSE: This phase II trial is studying how well zoledronate works in preventing osteoporosis in patients with...
Detailed Description
This is an open-labeled trial to determine the incidence of osteoporosis in brain tumor patients and effect of Zometa every three months. Zometa will be given at 4 mg intravenously over 15 minutes eve...
Eligibility Criteria
Inclusion
- Patients must have histologically confirmed diagnosis of a primary brain tumor.
- Patients must be on Depakote ( Valproic Acid) or one of the following enzyme inducing anticonvulsants (EIAC) therapies. Phenobarbital, Dilantin, Trileptal, Tegretol and/or on more than physiologic replacement steroid therapy (Dexamethasone \>0.75 mg/d, prednisone \>5 mg/d or hydrocortisone \>20 mg/d).
- Age \> 18 years.
- Karnofsky performance score \> 60%
- Adequate renal and liver function as demonstrated by laboratory values performed within 14 days, inclusive, prior to the administration of Zometa, except for the creatinine, which will be within 72 hs of Zometa administration:
- Serum creatinine \< 2.0 mg/dl and calculated creatinine clearance of \>60 mL/min
- Total serum bilirubin \< 1.5 times upper limit of laboratory normal
- Serum glutamoc-oxaloacetic transaminase (SGOT) and serum glutamic pyruvic transaminase (SGPT) \< 2.5 times upper limit of laboratory normal
- Alkaline phosphatase of \<2 times upper limit of laboratory normal
- Patients must have recovered from any effects of major surgery.
- Patients must have a life expectancy of greater than 12 weeks.
- Patients or legal guardian must give written, informed consent.
Exclusion
- Patients who are poor medical risks because of non-malignant systemic disease as well as those with acute infection treated with intravenous antibiotics.
- Previous or concurrent malignancies at other sites with the exception of surgically cured carcinoma in-situ of the cervix and basal or squamous cell carcinoma of the skin.
- Known HIV positivity or AIDS-related illness.
- Pregnant or nursing women.
- Women of childbearing potential who are not using an effective method of contraception. Women of childbearing potential must have a negative serum pregnancy test 72hours prior to administration of study and be practicing medically approved contraceptive precautions.
- Men who are not advised to use and effective method of contraception.
- Patients previously diagnosed with osteoporosis requiring oral bisphosphonates.
- Known hypersensitivity to Zometa® (zoledronic acid) or other bisphosphonates
- Current active dental problems including infection of the teeth or jawbone osteonecrosis of the jaw (ONJ), of exposed bone in the mouth, or of slow healing after dental procedures.
- Recent (within 6 weeks) or planned dental or jaw surgery (e.g.. extraction, implants).
Key Trial Info
Start Date :
May 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2012
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT00301873
Start Date
May 1 2006
End Date
September 1 2012
Last Update
February 18 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Duke Comprehensive Cancer Center
Durham, North Carolina, United States, 27710